ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,429Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 273

$809K Total Retail Price of All Prescriptions

Rank: 19 out of 273

790 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
15% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

0% of this provider’s 13,225 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
CARVEDILOL 1,449 1,284 1 3
SIMVASTATIN 647 602 2 6
METOPROLOL SUCCINATE 581 554 3 1
WARFARIN SODIUM 577 558 4 7
CRESTOR 535 504 5 14
ATORVASTATIN CALCIUM 522 488 6 8
FUROSEMIDE 490 458 7 5
DIGOXIN 421 413 8 15
AMLODIPINE BESYLATE 419 395 9 2
LOSARTAN POTASSIUM 399 383 10 19
ENALAPRIL MALEATE 365 304 11 31
POTASSIUM CHLORIDE 336 303 12 18
BISOPROLOL FUMARATE 302 273 13 45
METOPROLOL TARTRATE 299 273 14 10
DIOVAN 280 272 15 21
CLOPIDOGREL 252 226 16 9
CLONIDINE HCL 244 222 17 32
PLAVIX 214 203 18 12
LOVASTATIN 210 207 19 44
BYSTOLIC 207 159 20 26
LISINOPRIL 198 180 21 4
ZETIA 191 174 22 30
LIPITOR 176 169 23 29
ATENOLOL 171 149 24 17
PRADAXA 171 169 24 22
LEVOTHYROXINE SODIUM 170 132 26 25
SOTALOL 165 165 27 27
NITROSTAT 151 129 28 28
VYTORIN 146 128 29 68
HYDROCHLOROTHIAZIDE 144 112 30 16
NIFEDIPINE ER 143 136 31 43
RANEXA 140 125 32 37
SPIRONOLACTONE 127 113 33 20
RAMIPRIL 127 105 33 24
PRAVASTATIN SODIUM 127 126 33 11
OMEPRAZOLE 124 107 36 33
ISOSORBIDE MONONITRATE 120 120 37 113
LANOXIN 116 116 38 104
AMIODARONE HCL 114 95 39 23
MULTAQ 111 109 40 52
ZOLPIDEM TARTRATE 105 78 41 59
BENICAR 97 96 42 88
XARELTO 89 87 43 61
PANTOPRAZOLE SODIUM 88 73 44 41
PROPAFENONE HCL 82 82 45 57
NITROGLYCERIN PATCH 80 77 46 80
DIOVAN HCT 76 76 47 58
COREG CR 71 71 48 114
GEMFIBROZIL 67 57 49 83
KLOR-CON M20 65 65 50 39
AMLODIPINE BESYLATE-BENAZEPRIL 60 60 51 47
BENAZEPRIL HCL 58 51 52 35
ALPRAZOLAM 58 58 52 130
COUMADIN 56 56 54 50
BENICAR HCT 54 46 55 105
BISOPROLOL-HYDROCHLOROTHIAZIDE 52 49 56 84
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 11, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.